Efficacy and Safety of Multimodal Ablation Combined With PD-1 Monoclonal Antibody, Lenvatinib and TACE in the Treatment of Unresectable Primary Hepatocellular Carcinoma: A Single-Arm, Single-Center Clinical Study

This study is a prospective, single-arm, single-center trial evaluating the efficacy of TACE combined with multimodal ablation, Tislelizumab, and lenvatinib in the treatment of unresectable primary liver cancer.

Trial Details

NCT ID
NCT06794073
Phase
NA
Sponsor
Shanghai Zhongshan Hospital
Status
RECRUITING
Cancer Type
Liver Cancer
Interventions
  • Multimodal Thermal Therapy
Locations (sample)
  • Shanghai, Shanghai Municipality, China|31.22222,121.45806

Key Eligibility Criteria

  • Age 18-80 years, regardless of gender.
  • Clinically or pathologically confirmed HCC.
  • CNLC stage IIb-IIIa, deemed unresectable after multidisciplinary evaluation.
  • Having radiologically evaluable, untreated target lesions for ablation, with the largest diameter of the target tumor \>5 cm.

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Liver Cancer Trials on Trialify →